Clear Cell Renal Cell Carcinoma: From Biology to Treatment
暂无分享,去创建一个
[1] T. Choueiri,et al. Upfront Cytoreductive Nephrectomy for Metastatic Renal Cell Carcinoma Treated with Immune Checkpoint Inhibitors or Targeted Therapy: An Observational Study from the International Metastatic Renal Cell Carcinoma Database Consortium. , 2022, European urology.
[2] R. Hannan,et al. The Emerging Role of Radiation Therapy in Renal Cell Carcinoma , 2022, Cancers.
[3] T. Powles,et al. Pembrolizumab as post nephrectomy adjuvant therapy for patients with renal cell carcinoma: Results from 30-month follow-up of KEYNOTE-564. , 2022, Journal of Clinical Oncology.
[4] W. Linehan,et al. Belzutifan for Renal Cell Carcinoma in von Hippel-Lindau Disease. , 2021, The New England journal of medicine.
[5] F. Lohr,et al. Nivolumab in Combination with Stereotactic Body Radiotherapy in Pretreated Patients with Metastatic Renal Cell Carcinoma. Results of the Phase II NIVES Study. , 2021, European urology.
[6] M. Burotto,et al. 661P Conditional survival and 5-year follow-up in CheckMate 214: First-line nivolumab + ipilimumab (N+I) versus sunitinib (S) in advanced renal cell carcinoma (aRCC) , 2021, Annals of Oncology.
[7] J. Burke,et al. Adjuvant Pembrolizumab after Nephrectomy in Renal-Cell Carcinoma. , 2021, The New England journal of medicine.
[8] R. Hannan,et al. Stereotactic Ablative Radiation Therapy for Oligoprogressive Renal Cell Carcinoma , 2021, Advances in radiation oncology.
[9] T. Powles,et al. Pembrolizumab (pembro) plus axitinib (axi) versus sunitinib as first-line therapy for advanced clear cell renal cell carcinoma (ccRCC): Results from 42-month follow-up of KEYNOTE-426. , 2021, Journal of Clinical Oncology.
[10] Jianqing Lin,et al. Hypoxia-Inducible Factor-2α as a Novel Target in Renal Cell Carcinoma , 2021, Journal of kidney cancer and VHL.
[11] C. Porta,et al. Nivolumab plus Cabozantinib versus Sunitinib for Advanced Renal-Cell Carcinoma. , 2021, The New England journal of medicine.
[12] R. Motzer,et al. Efficacy and safety of avelumab plus axitinib (A + Ax) versus sunitinib (S) in elderly patients with advanced renal cell carcinoma (aRCC): Extended follow-up results from JAVELIN Renal 101. , 2021 .
[13] C. Porta,et al. Lenvatinib plus Pembrolizumab or Everolimus for Advanced Renal Cell Carcinoma. , 2021, The New England journal of medicine.
[14] K. Decaestecker,et al. Current role of cytoreductive nephrectomy in metastatic renal cell carcinoma. , 2021, Turkish journal of urology.
[15] Andrew P. Voigt,et al. Mapping the immune environment in clear cell renal carcinoma by single-cell genomics , 2021, Communications biology.
[16] A. Jemal,et al. Cancer Statistics, 2021 , 2021, CA: a cancer journal for clinicians.
[17] C. Wood,et al. The current role of cytoreductive nephrectomy for metastatic renal cell carcinoma , 2021, Indian journal of urology : IJU : journal of the Urological Society of India.
[18] Amber C. Donahue,et al. Avelumab plus axitinib versus sunitinib in advanced renal cell carcinoma: biomarker analysis of the phase 3 JAVELIN Renal 101 trial , 2020, Nature Medicine.
[19] F. D. De Braud,et al. Predictive Biomarkers of Response to Immunotherapy in Metastatic Renal Cell Cancer , 2020, Frontiers in Oncology.
[20] P. Ross-Macdonald,et al. Biomarker analyses from the phase III CheckMate 214 trial of nivolumab plus ipilimumab (N+I) or sunitinib (S) in advanced renal cell carcinoma (aRCC). , 2020 .
[21] A. Mohammed,et al. Epidemiology of Renal Cell Carcinoma , 2020, World journal of oncology.
[22] B. Dai,et al. Tumor-infiltrating CD39+CD8+ T cells determine poor prognosis and immune evasion in clear cell renal cell carcinoma patients , 2020, Cancer Immunology, Immunotherapy.
[23] D. Song,et al. Combination of dual immune checkpoint inhibition (ICI) with stereotactic radiation (SBRT) in metastatic renal cell carcinoma (mRCC) (RADVAX RCC). , 2020 .
[24] C. Porta,et al. Tivozanib versus sorafenib in patients with advanced renal cell carcinoma (TIVO-3): a phase 3, multicentre, randomised, controlled, open-label study. , 2019, The Lancet. Oncology.
[25] R. Hannan,et al. Stereotactic Ablative Radiotherapy (SAbR) Used to Defer Systemic Therapy in Oligometastatic Renal Cell Cancer. , 2019, International journal of radiation oncology, biology, physics.
[26] G. Freeman,et al. PD-L1 Expression and Clinical Outcomes to Cabozantinib, Everolimus, and Sunitinib in Patients with Metastatic Renal Cell Carcinoma: Analysis of the Randomized Clinical Trials METEOR and CABOSUN , 2019, Clinical Cancer Research.
[27] O. Elemento,et al. Radiation therapy and anti-tumor immunity: exposing immunogenic mutations to the immune system , 2019, Genome medicine.
[28] K. Bensalah,et al. Cytoreductive nephrectomy (CN) in metastatic renal cancer (mRCC): Update on Carmena trial with focus on intermediate IMDC-risk population. , 2019, Journal of Clinical Oncology.
[29] Y. Ouyang,et al. Immune infiltration in renal cell carcinoma , 2019, Cancer science.
[30] S. Kim,et al. Phytochemicals Targeting VEGF and VEGF-Related Multifactors as Anticancer Therapy , 2019, Journal of clinical medicine.
[31] T. Powles,et al. Pembrolizumab plus Axitinib versus Sunitinib for Advanced Renal‐Cell Carcinoma , 2019, The New England journal of medicine.
[32] R. Motzer,et al. Avelumab plus Axitinib versus Sunitinib for Advanced Renal‐Cell Carcinoma , 2019, The New England journal of medicine.
[33] E. Borden. Interferons α and β in cancer: therapeutic opportunities from new insights , 2019, Nature Reviews Drug Discovery.
[34] R.C.E. van Velthoven,et al. Comparison of Immediate vs Deferred Cytoreductive Nephrectomy in Patients With Synchronous Metastatic Renal Cell Carcinoma Receiving Sunitinib: The SURTIME Randomized Clinical Trial , 2019, JAMA oncology.
[35] V. Kalia,et al. Regulation of Effector and Memory CD8 T Cell Differentiation by IL-2—A Balancing Act , 2018, Front. Immunol..
[36] E. V. Van Allen,et al. Genomics of response to immune checkpoint therapies for cancer: implications for precision medicine , 2018, Genome Medicine.
[37] K. Bensalah,et al. Sunitinib Alone or after Nephrectomy in Metastatic Renal‐Cell Carcinoma , 2018, The New England journal of medicine.
[38] Bohuslav Melichar,et al. Nivolumab plus Ipilimumab versus Sunitinib in Advanced Renal‐Cell Carcinoma , 2018, The New England journal of medicine.
[39] G. Zeng,et al. Crosstalk between VEGFR and other receptor tyrosine kinases for TKI therapy of metastatic renal cell carcinoma , 2018, Cancer Cell International.
[40] M. Kaushik,et al. A Review of Von Hippel-Lindau Syndrome , 2017, Journal of kidney cancer and VHL.
[41] Michael B. Stadler,et al. An Immune Atlas of Clear Cell Renal Cell Carcinoma , 2017, Cell.
[42] Xueying Sun,et al. Development of Inhibitors Targeting Hypoxia-Inducible Factor 1 and 2 for Cancer Therapy , 2017, Yonsei medical journal.
[43] Xinwei Zhang,et al. PD-1 and its ligands are important immune checkpoints in cancer , 2016, Oncotarget.
[44] D. Speiser,et al. Regulatory circuits of T cell function in cancer , 2016, Nature Reviews Immunology.
[45] P. Venkat,et al. Systematic review of case reports on the abscopal effect. , 2016, Current problems in cancer.
[46] C. Porta,et al. Prognostic Role of PD-L1 Expression in Renal Cell Carcinoma. A Systematic Review and Meta-Analysis , 2016, Targeted Oncology.
[47] A. Ravaud,et al. Nivolumab versus Everolimus in Advanced Renal-Cell Carcinoma. , 2015, The New England journal of medicine.
[48] P. Kantoff,et al. Cabozantinib versus Everolimus in Advanced Renal-Cell Carcinoma. , 2015, The New England journal of medicine.
[49] J. Larkin,et al. Lenvatinib, everolimus, and the combination in patients with metastatic renal cell carcinoma: a randomised, phase 2, open-label, multicentre trial. , 2015, The Lancet. Oncology.
[50] J. Gore,et al. Trends in Metastatic Kidney Cancer Survival From the Cytokine to the Targeted Therapy Era. , 2015, Urology.
[51] E. Wherry,et al. Molecular and cellular insights into T cell exhaustion , 2015, Nature Reviews Immunology.
[52] C. Porta,et al. Inhibition of the VEGF/VEGFR pathway improves survival in advanced kidney cancer: a systematic review and meta-analysis. , 2015, Current drug targets.
[53] R. Weichselbaum,et al. Irradiation and anti-PD-L1 treatment synergistically promote antitumor immunity in mice. , 2014, The Journal of clinical investigation.
[54] J. Reeves,et al. Pazopanib versus sunitinib in metastatic renal-cell carcinoma. , 2013, The New England journal of medicine.
[55] W. Rathmell,et al. The molecular biology of renal cell carcinoma. , 2013, Seminars in oncology.
[56] T. Choueiri,et al. External validation and comparison with other models of the International Metastatic Renal-Cell Carcinoma Database Consortium prognostic model: a population-based study. , 2013, The Lancet. Oncology.
[57] D. Gabrilovich,et al. Coordinated regulation of myeloid cells by tumours , 2012, Nature Reviews Immunology.
[58] Eli Gilboa,et al. The determinants of tumour immunogenicity , 2012, Nature Reviews Cancer.
[59] J. Sprent,et al. The role of interleukin-2 during homeostasis and activation of the immune system , 2012, Nature Reviews Immunology.
[60] R. Motzer,et al. Comparative effectiveness of axitinib versus sorafenib in advanced renal cell carcinoma (AXIS): a randomised phase 3 trial , 2011, The Lancet.
[61] R. Schreiber,et al. Cancer Immunoediting: Integrating Immunity’s Roles in Cancer Suppression and Promotion , 2011, Science.
[62] A. Ravaud,et al. Phase III trial of bevacizumab plus interferon alfa-2a in patients with metastatic renal cell carcinoma (AVOREN): final analysis of overall survival. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[63] C. Sternberg,et al. Pazopanib in Locally Advanced or Metastatic Renal Cell Carcinoma: Results of a Randomized Phase III Trial , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[64] Wanling Xie,et al. Prognostic factors for overall survival in patients with metastatic renal cell carcinoma treated with vascular endothelial growth factor-targeted agents: results from a large, multicenter study. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[65] J. Zimmer,et al. Cytokine Levels Correlate with Immune Cell Infiltration after Anti-VEGF Therapy in Preclinical Mouse Models of Breast Cancer , 2009, PloS one.
[66] D. McDermott,et al. The high-dose aldesleukin (IL-2) "select" trial: a trial designed to prospectively validate predictive models of response to high-dose IL-2 treatment in patients with metastatic renal cell carcinoma. , 2009, Clinical genitourinary cancer.
[67] R. Motzer,et al. Efficacy of everolimus in advanced renal cell carcinoma: a double-blind, randomised, placebo-controlled phase III trial , 2008, The Lancet.
[68] F. Waldman,et al. Improved Identification of von Hippel-Lindau Gene Alterations in Clear Cell Renal Tumors , 2008, Clinical Cancer Research.
[69] S. Steinberg,et al. High‐dose interleukin‐2 for the treatment of metastatic renal cell carcinoma , 2008, Cancer.
[70] Bohuslav Melichar,et al. Bevacizumab plus interferon alfa-2a for treatment of metastatic renal cell carcinoma: a randomised, double-blind phase III trial , 2007, The Lancet.
[71] David McDermott,et al. Temsirolimus, interferon alfa, or both for advanced renal-cell carcinoma. , 2007, The New England journal of medicine.
[72] Apurva A Desai,et al. Sorafenib in advanced clear-cell renal-cell carcinoma. , 2007, The New England journal of medicine.
[73] R. Figlin,et al. Sunitinib versus interferon alfa in metastatic renal-cell carcinoma. , 2007, The New England journal of medicine.
[74] E. Henske,et al. Activation of the mTOR signaling pathway in renal clear cell carcinoma. , 2007, The Journal of urology.
[75] I. Mellinghoff,et al. Hypoxia-inducible factor determines sensitivity to inhibitors of mTOR in kidney cancer , 2006, Nature Medicine.
[76] R. Parker,et al. Histologic Predictors of Renal Cell Carcinoma Response to Interleukin-2-Based Therapy , 2005, Journal of immunotherapy.
[77] R. Flanigan. Debulking Nephrectomy in Metastatic Renal Cancer , 2004, Clinical Cancer Research.
[78] W. Kaelin,et al. The von Hippel-Lindau gene, kidney cancer, and oxygen sensing. , 2003, Journal of the American Society of Nephrology : JASN.
[79] G. Palapattu,et al. Paraneoplastic syndromes in urologic malignancy: the many faces of renal cell carcinoma. , 2002, Reviews in urology.
[80] G. Köhler,et al. Pro-Inflammatory and T Cell Inhibitory Cytokines Are Secreted at High Levels in Tumor Cell Cultures of Human Renal Cell Carcinoma , 1999, European Urology.
[81] R. Fisher,et al. Results of treatment of 255 patients with metastatic renal cell carcinoma who received high-dose recombinant interleukin-2 therapy. , 1995, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[82] R. Motzer,et al. Interferon alfa-2a in advanced renal cell carcinoma: treatment results and survival in 159 patients with long-term follow-up. , 1993, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[83] J. Gnarra,et al. Identification of the von Hippel-Lindau disease tumor suppressor gene. , 1993, Science.
[84] C. Logothetis,et al. Surgery following response to interferon-α-based therapy for residual renal cell carcinoma , 1993 .
[85] J. Haines,et al. Von HippelLindau disease maps to the region of chromosome 3 associated with renal cell carcinoma , 1988, Nature.
[86] H. Muss. Interferon therapy of metastatic renal cell cancer. , 1988, Seminars in surgical oncology.
[87] L. Peters,et al. Effect of host immune capability on radiocurability and subsequent transplantability of a murine fibrosarcoma. , 1979, Journal of the National Cancer Institute.
[88] S. Freed. Nephrectomy for renal cell carcinoma with metastases. , 1977, Urology.
[89] D. Taylor,et al. Spontaneous regression of pulmonary metastases following palliative nephrectomy. Case report , 1967, Cancer.
[90] P. Gonick,et al. REGRESSION OF PULMONARY METASTASES FROM RENAL ADENOCARCINOMA. , 1964, The Journal of urology.
[91] K. Melmon,et al. Lindau's disease: Review of the literature and study of a large kindred , 1964 .
[92] A. Sakula. SPONTANEOUS REGRESSION OF PULMONARY METASTASES SECONDARY TO CARCINOMA OF KIDNEY. , 1963, British journal of diseases of the chest.
[93] M. Karno,et al. Renal cell carcinoma. , 1956, Bulletin. Tufts-New England Medical Center.
[94] Jianqing Lin,et al. Hypoxia-Inducible Factor-2 Alpha as a Novel Target in Renal Cell Carcinoma , 2022, Journal of Kidney Cancer and VHL.